Tempus, a Chicago-based health IT technology company focused on collecting and integrating molecular and clinical data has announced a collaboration with Sanford Health to identify targeted therapies and clinical trials for breast cancer patients. Founded in 2015, Tempus continues to expand its network of partners and is currently working with leading academic medical centers, NCI designated cancer centers, hospital networks and community oncologists across the United States. As part of the
Read More
Personalized Medicine | Digital Health | News, Analysis, Insights - HIT Consultant
Tempus, Cleveland Clinic Collaborate on Personalized Cancer Medicine Initiative
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.As part of the research collaboration spanning multiple cancer subtypes, Tempus will provide molecular sequencing and analysis for patients enrolled in a precision oncology clinical
Read More
University of California Davis, Tempus Partner on Personalized Cancer Initiative
University of California Davis Comprehensive Cancer Center is collaborating with technology company Tempus on a precision medicine partnership. The new collaboration will focus on advancing clinical care with Next Generation Sequencing analysis for patients diagnosed with hematological malignancies and pancreatic cancer.Collaboration DetailsTempus will perform molecular sequencing and analysis for a group of patients at UC Davis Comprehensive Cancer Center. Utilizing machine learning and
Read More
University of California San Diego, Tempus Partner on Personalized Medicine Initiative
Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, will provide Moores Cancer Center at UC San Diego Health with molecular sequencing, analysis and decision support tools to enable further research on immune checkpoint inhibitors across cancer types. Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare
Read More
University of Michigan, Tempus Partner on Personalized Breast Cancer Medicine Initiative
Breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women. In 2017, it is estimated that more than 250,000 U.S. women will be diagnosed with new cases of invasive breast cancer. That’s why the University of Michigan Comprehensive Cancer Center has partnered with Tempus on a personalized cancer medicine initiative aimed providing most effective care for individuals diagnosed with breast cancer.As part of the initiative, Tempus will use
Read More
Precision Medicine Startup AltheaDx Lands $27M to Expand Personalized Therapeutic Decisions Internationally
AltheaDx, Inc., a San Diego, CA-based commercial stage molecular diagnostics company specializing in the field of personalized medicine has raised $27 million in Series D funding. The company is a CAP-accredited, CLIA-certified laboratory and plans to utilize the funding to expands its sales force and marketing efforts to grow internationally.IDgenetix, the company’s product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent
Read More
3 Keys to Achieving Clinically Actionable Precision Medicine for Providers
Oracle’s Jonathan Sheldon shares his perspective on precision medicine and explains how providers can prepare for the transformation that lies ahead.The term personalized healthcare may seem like a buzzword, but it’s real and developing faster than imagined in the form of precision medicine. Using a patient’s genetic profile in conjunction with lifestyle and environmental variables to create individual treatment plans—what could be more personal than that?Thanks to technology, we are starting to
Read More
Report: Personalized Medicine Is Having A Positive Measurable Effect on Patient Outcomes
A new approach to research, pharmaceutical development, and clinical care is remaking healthcare. Known as personalized medicine or precision medicine, it promises improved patient outcomes, cost savings, and progress against previously intractable illnesses. Yet substantial challenges remain to be addressed if personalized medicine is to deliver on its potential. A new research program from Oxford Economics shows what healthcare and pharmaceutical organizations are doing to hasten this
Read More
20 Promising Canadian Digital Health Companies to Watch
“A company’s odds of success are better the closer they can get to their market,” argues Stephen Hurwitz, a thought leader in the Canadian venture capital industry, recognizing that the proximity to a VC-tech hub can help the success rate of Canadian startups. A socialized healthcare system, Canada’s market is fragmented by province and type of care – most primary and emergency care is free for residents whereas specialty care, prescription drugs, long-term and in-home care amongst others,
Read More
Rock Health: How Predictive Analytics Impacts Patient Care
As data sources and technology advance, algorithms will be able to deliver better, personalized care. Though personalized medicine has yet to deliver on the promise of its powers, its precursor, predictive analytics, has proven effective in many industries and is now focused on transforming healthcare. Dozens of new digital health products have hit the market and $1.9B has flowed into the space since 2011—but what does it take for an algorithm to accurately and reliably impact care? Rock
Read More
